Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.66 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18266282 | 0.85 | IDO1 (0.49) | IDO1PYCR1LOXL2CSNK2A1LOX | |
| SCHEMBL717599 | 0.84 | DAO (0.48) | IDO1LOXL2CSNK2A1LOXNOTUM | |
| SCHEMBL30152373 | 0.84 | DAO (0.48) | IDO1LOXL2CSNK2A1LOXNOTUM | |
| SCHEMBL10656615 | 0.83 | IDO1 (0.65) | IDO1PYCR1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL3236687 | 0.83 | IDO1 (0.63) | IDO1PYCR1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL30152380 | 0.82 | IDO1 (0.49) | IDO1LOXL2CSNK2A1LOXPNMT | |
| SCHEMBL932921 | 0.82 | IDO1 (0.62) | IDO1PYCR1HTR3EHTR3BHTR3A | |
| SCHEMBL875395 | 0.81 | IDO1 (0.54) | IDO1GPR84LOXL2LOX | |
| SCHEMBL8690013 | 0.81 | LOXL2 (0.47) | IDO1PYCR1LOXL2LOX | |
| SCHEMBL24969799 | 0.80 | IDO1 (0.61) | IDO1PYCR1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105505128-B | Near-infrared light response self-repairing coating and preparation method thereof | 南京工业大学 | 2018-05-08 | — | — | CN | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| EP-3487836-B1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF | UNIV COLUMBIA (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12239618-B2 | Histone acetyltransferase activators and compositions and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2024249380-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-115093389-B | 6-Amide chroman-3-carboxamide derivative, preparation method and application thereof | 广州医科大学 | 2024-10-18 | — | — | CN | disclosed |
| EP-3626718-B1 | FIVE-MEMBERED-FUSED-SIX-MEMBERED AZA-AROMATIC RING COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | UNIV XIAMEN (CN) | 2024-05-15 | — | — | EP | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2002013824-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| US-20020010174-A1 | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| WO-2001090083-A1 | 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0212479-A1 | Use of lactam amides as efficiency improvers in animals | BAYER AG (DE) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | IDO1 3872/4885PYCR1 2208/4885HTR3E 2085/4885 |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | IDO1 2053/4885PYCR1 3347/4885HTR3E 1343/4885 |
| US-12239618-B2 | Histone acetyltransferase activators and compositions and uses thereof | HDAC6, HDAC9, HDAC5 | IDO1 2851/4885PYCR1 4015/4885HTR3E 1336/4885 |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | MAOB, CYP2F1, AGL | IDO1 49/4885PYCR1 2427/4885HTR3E 3091/4885 |
| US-20020010174-A1 | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation | BDKRB2, NPSR1, BDKRB1 | IDO1 840/4885PYCR1 1869/4885HTR3E 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.